LeonaBio Q2 FY26 net loss widens to $19 million; R&D expenses more than doubled to $12.9 million
LONA•Cash position and trial progress
Cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, from $88.3 million at the end of 2025.
ELAINE-3 enrolled 495 patients; enrollment of about 600 remains on track for 4Q 2026, with topline data expected in 2H 2027.
Quarterly loss and expenses widen
LeonaBio posted a net loss of $19 million, or $0.80 per share, for the quarter ended June 30, 2026.
Research and development expense more than doubled to $12.9 million, driven primarily by higher ELAINE-3 clinical trial spending.
General and administrative costs rose to $6.6 million from $3.6 million a year earlier on higher personnel-related and professional service expenses.
Related News
Harte Hanks Q2 FY26 net loss widens to $5 million; revenue falls 1.7% to $37.98 million
HHS•
Pioneer Power Q2 FY26 net loss widens to USD 2.06 million; revenue drops 40% to USD 5.02 million
PPSI•
